Cargando…

First-line pazopanib in patients with advanced non-clear cell renal carcinoma: An Italian case series

BACKGROUND: Non-clear cell (ncc) metastatic renal-cell carcinoma (RCC) has dismal results with standard systemic therapies and a generally worse prognosis when compared to its clear-cell counterpart. New systemic combination therapies have emerged for metastatic RCC (mRCC), but the pivotal phase III...

Descripción completa

Detalles Bibliográficos
Autores principales:	Buti, Sebastiano, Bersanelli, Melissa, Massari, Francesco, De Giorgi, Ugo, Caffo, Orazio, Aurilio, Gaetano, Basso, Umberto, Carteni, Giacomo, Caserta, Claudia, Galli, Luca, Boccardo, Francesco, Procopio, Giuseppe, Facchini, Gaetano, Fornarini, Giuseppe, Berruti, Alfredo, Fea, Elena, Naglieri, Emanuele, Petrelli, Fausto, Iacovelli, Roberto, Porta, Camillo, Mosca, Alessandra
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2021
Materias:	Retrospective Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8641010/ https://www.ncbi.nlm.nih.gov/pubmed/34909398 http://dx.doi.org/10.5306/wjco.v12.i11.1037

Ejemplares similares

Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib
por: Rebuzzi, Sara Elena, et al.
Publicado: (2022)

Sequential Treatment with Pazopanib and Everolimus in Metastatic Renal Cell Carcinoma
por: Rossetti, Sabrina, et al.
Publicado: (2017)

Second-line treatment in renal cell carcinoma: clinical experience and decision making
por: Guadalupi, Valentina, et al.
Publicado: (2021)

Predictors of long-term response to abiraterone in patients with metastastic castration-resistant prostate cancer: a retrospective cohort study
por: Verzoni, Elena, et al.
Publicado: (2016)

Pazopanib as a possible option for the treatment of metastatic non-clear cell renal carcinoma patients: a systematic review
por: Bersanelli, Melissa, et al.
Publicado: (2020)

GU-CA-COVID: a clinical audit among Italian genitourinary oncologists during the first COVID-19 outbreak
por: Bersanelli, Melissa, et al.
Publicado: (2021)

On the relationship between androgen-deprivation therapy for prostate cancer and risk of infection by SARS-CoV-2
por: Caffo, O., et al.
Publicado: (2020)

Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study)
por: Bersanelli, Melissa, et al.
Publicado: (2021)

Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor?
por: Santoni, Matteo, et al.
Publicado: (2021)

Effect of systemic therapies or best supportive care after disease progression to both nivolumab and cabozantinib in metastatic renal cell carcinoma: The Meet‐Uro 19BEYOND study
por: Roviello, Giandomenico, et al.
Publicado: (2022)

Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone
por: Lolli, Cristian, et al.
Publicado: (2016)

Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors
por: Santoni, Matteo, et al.
Publicado: (2019)

The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 study
por: Rebuzzi, Sara Elena, et al.
Publicado: (2022)

The prognostic value of baseline and early variations of peripheral blood inflammatory ratios and their cellular components in patients with metastatic renal cell carcinoma treated with nivolumab: The Δ-Meet-URO analysis
por: Rebuzzi, Sara Elena, et al.
Publicado: (2022)

Immune checkpoint inhibitors in adjuvant setting after radical resection of melanoma: a meta-analysis of the pivotal trials
por: Bersanelli, Melissa, et al.
Publicado: (2021)

Impact of Previous Nephrectomy on Clinical Outcome of Metastatic Renal Carcinoma Treated With Immune-Oncology: A Real-World Study on Behalf of Meet-URO Group (MeetUro-7b)
por: Stellato, Marco, et al.
Publicado: (2021)

Is there a preferred first-line therapy for metastatic renal cell carcinoma? A network meta-analysis
por: Cattrini, Carlo, et al.
Publicado: (2021)

Pazopanib and pancreatic toxicity: a case report
por: Russano, Marco, et al.
Publicado: (2015)

The Geriatric G8 Score Is Associated with Survival Outcomes in Older Patients with Advanced Prostate Cancer in the ADHERE Prospective Study of the Meet-URO Network
por: Banna, Giuseppe Luigi, et al.
Publicado: (2022)

Renal cell carcinoma and viral infections: A dangerous relationship?
por: Bersanelli, Melissa, et al.
Publicado: (2022)

Sodium Levels and Outcomes in Patients With Metastatic Renal Cell Carcinoma Receiving Nivolumab
por: Catalano, Martina, et al.
Publicado: (2023)

Spotlight on cabozantinib for previously untreated advanced renal cell carcinoma: evidence to date
por: Bersanelli, Melissa, et al.
Publicado: (2018)

Morphologic, Molecular and Clinical Features of Aggressive Variant Prostate Cancer
por: Montironi, Rodolfo, et al.
Publicado: (2020)

Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma?
por: Grassi, Paolo, et al.
Publicado: (2017)

Metabolomic Profiling in Renal Cell Carcinoma Patients: News and Views
por: Aurilio, Gaetano, et al.
Publicado: (2021)

An Italian multicenter retrospective real-life analysis of patients with brain metastases from renal cell carcinoma: the BMRCC study
por: Internò, V., et al.
Publicado: (2023)

Inflammatory indices and clinical factors in metastatic renal cell carcinoma patients treated with nivolumab: the development of a novel prognostic score (Meet-URO 15 study)
por: Rebuzzi, Sara Elena, et al.
Publicado: (2021)

New Frontiers in Prostate Cancer Treatment: Are We Ready for Drug Combinations with Novel Agents?
por: Aurilio, Gaetano, et al.
Publicado: (2020)

Update on Circulating Tumor Cells in Genitourinary Tumors with Focus on Prostate Cancer
por: Cimadamore, Alessia, et al.
Publicado: (2020)

Narrative review: update on immunotherapy and pathological features in patients with bladder cancer
por: Aurilio, Gaetano, et al.
Publicado: (2021)

Bone metastases in patients with metastatic renal cell carcinoma: are they always associated with poor prognosis?
por: Santoni, Matteo, et al.
Publicado: (2015)

BRCA Mutations in Prostate Cancer: Prognostic and Predictive Implications
por: Messina, Carlo, et al.
Publicado: (2020)

The right immune-modulation at the right time: thymosin α1 for prevention of severe COVID-19 in cancer patients
por: Bersanelli, Melissa, et al.
Publicado: (2021)

Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma
por: Leonetti, Alessandro, et al.
Publicado: (2017)

Compassionate Use Program of Ipilimumab and Nivolumab in Intermediate or Poor Risk Metastatic Renal Cell Carcinoma: A Large Multicenter Italian Study
por: Basso, Umberto, et al.
Publicado: (2022)

Adherence to Oral Treatments in Older Patients with Advanced Prostate Cancer, the ADHERE Study: A Prospective Trial of the Meet-URO Network
por: Rescigno, Pasquale, et al.
Publicado: (2022)

Concomitant Drugs Prognostic Score in Patients With Metastatic Renal Cell Carcinoma Receiving Ipilimumab and Nivolumab in the Compassionate Use Program in Italy: Brief Communication
por: Buti, Sebastiano, et al.
Publicado: (2023)

Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications
por: Aurilio, Gaetano, et al.
Publicado: (2020)

Pazopanib in Metastatic Renal Cancer: A “Real-World” Experience at National Cancer Institute “Fondazione G. Pascale”
por: Cecere, Sabrina C., et al.
Publicado: (2016)

Immune Checkpoint Inhibitors in Advanced Prostate Cancer: Current Data and Future Perspectives
por: Rebuzzi, Sara Elena, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qge34r4quon90ccts7ho4rjm8d